Janssen Biologics BV ▲ Sign in to save

• ▲ Anja B. Geldhof

  Janssen (Netherlands) Immunology and Microbiology
  1.13k

  citations

  16

  h-index

  18

  Aachen papers
• ▲ Bassey Effiom Edem

  Johnson & Johnson (United States) · Johnson & Johnson (Netherlands) Immunology and Microbiology
  567

  citations

  12

  h-index

  1

  Aachen papers
• ▲ Richard Melsheimer

  Biochemistry, Genetics and Molecular Biology
  470

  citations

  10

  h-index

  6

  Aachen papers
• ▲ Britte Kranenburg

  Janssen (Netherlands) Medicine
  355

  citations

  7

  h-index

  1

  Aachen papers
• ▲ Bart van Hartingsveldt

  Janssen (Netherlands) · Johnson & Johnson (Netherlands) Medicine
  294

  citations

  6

  h-index

  6

  Aachen papers
• ▲ Cécile Spiertz

  Janssen (Netherlands) Mathematics
  152

  citations

  6

  h-index

  3

  Aachen papers
• ▲ Marijo Otero‐Lobato

  Johnson & Johnson (Netherlands) Pharmacology, Toxicology and Pharmaceutics
  45

  citations

  3

  h-index

  6

  Aachen papers
• ▲ Just Weemers

  Janssen (Netherlands) Economics, Econometrics and Finance
  18

  citations

  3

  h-index

  2

  Aachen papers
• ▲ Jacob Cornelis Bot

  Lygature · Janssen (Netherlands) Pharmacology, Toxicology and Pharmaceutics
  4

  citations

  1

  h-index

  1

  Aachen papers
• ▲ Suzan Esslinger

  Janssen (Belgium) Medicine
  2

  citations

  1

  h-index

  2

  Aachen papers

10 results

• Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

  2023 EClinicalMedicine article Mathematics Statistical Methods in Clinical Trials Open access

  48

  citations
• The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable

  2021 Advances in Therapy editorial Immunology and Microbiology Biosimilars and Bioanalytical Methods Open access

  38

  citations
• Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study

  2024 British Journal of Dermatology article Immunology and Microbiology Psoriasis: Treatment and Pathogenesis Open access

  12

  citations
• Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab

  2022 Current Medical Research and Opinion article Immunology and Microbiology Biosimilars and Bioanalytical Methods Open access

  10

  citations
• Exposure to golimumab during pregnancy: Results from the Company's global safety database

  2024 Pharmacology Research & Perspectives article Medicine Pregnancy and Medication Impact Open access

  8

  citations
• Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data

  2023 American Journal of Hematology article Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes Open access

  5

  citations
• The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report

  2024 Clinical Pharmacology & Therapeutics article Pharmacology, Toxicology and Pharmaceutics Pharmaceutical industry and healthcare Open access

  4

  citations
• Pregnancy and Infant Outcomes After Prenatal Exposure to Golimumab in Denmark, Finland, and Sweden 2006–2019

  2024 Pharmacoepidemiology and Drug Safety article Medicine Pregnancy and Medication Impact Open access

  3

  citations
• Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes

  2024 Drugs in R&D article Medicine Streptococcal Infections and Treatments Open access

  3

  citations
• Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders

  2021 Frontiers in Medicine article Medicine Biomedical Ethics and Regulation Open access

  3

  citations
• P599 Trimester exposure and pregnancy outcomes in women exposed to golimumab: Results from the company pharmacovigilance database

  2020 Journal of Crohn s and Colitis conference-abstract Medicine Pregnancy and Medication Impact

  1

  citations
• SAT0117 TRIMESTER EXPOSURE AND PREGNANCY OUTCOMES IN WOMEN EXPOSED TO GOLIMUMAB – RESULTS FROM THE COMPANY PHARMACOVIGILANCE DATABASE

  2020 Annals of the Rheumatic Diseases conference-abstract Medicine Pregnancy and Medication Impact Open access

  1

  citations
• Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627

  2022 Current Medical Research and Opinion letter Immunology and Microbiology Biosimilars and Bioanalytical Methods Open access

  0

  citations
• LB1531B. Administration of the TNF-alpha inhibitor, infliximab, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial

  2022 Open Forum Infectious Diseases article Medicine COVID-19 Clinical Research Studies Open access

  0

  citations
• 63549 Guselkumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients: results of a phase 3, randomized, placebo-controlled study

  2025 Journal of the American Academy of Dermatology article Immunology and Microbiology Psoriasis: Treatment and Pathogenesis

  0

  citations

15 results